ArticlesSequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial
Introduction
Gastric cancer is the fourth most common cancer worldwide and the second leading cause of cancer mortality.1 The prognosis of locally advanced tumours remains poor despite advances in adjuvant chemotherapy.2, 3, 4 More effective adjuvant chemotherapy treatments are needed for curatively resected but locally advanced gastric cancer.
Oral fluoropyrimidines and taxanes are often used to treat both gastric and breast cancer,5, 6, 7 and taxanes are important drugs for breast and ovarian cancer given singly or in combination.8, 9 Docetaxel provided modest but better survival than did paclitaxel every 3 weeks in a trial of advanced breast cancer; but its toxic effects were worse,10 and it has not been compared with dose-dense paclitaxel once per week, which is superior to paclitaxel every 3 weeks for ovarian cancer.9, 11 Sequential treatment with single taxanes is often preferred owing to fewer toxic effects and quality of life seems to be better.12, 13
Peritoneal metastasis are the most common site of relapse in patients with gastric cancer,3 for whom serosal exposure is a major risk.14, 15 Paclitaxel is effective for treatment of malignant ascites from gastric cancer,16 and in studies17, 18 of paclitaxel for the second-line chemotherapy, it was especially effective for peritoneal metastasis. Fluoropyrimidine monotherapy has been used for adjuvant chemotherapy in Asia, and a combination of tegafur and uracil (UFT) was for a time the Japanese community standard treatment for gastric cancer because of its efficacy, good compliance, and safety.5 In 2007, the NSAS-GC study19 showed that UFT plus surgery was more effective than surgery alone for Japanese patients who had had a D2 dissection for T2 and lymph node positive gastric cancer. UFT has since been replaced by S-1 in Japan because of the results of ACTS-GC,3 which was a large randomised controlled trial for stage II and III tumours, although no direct comparison of these two drugs has been done. Combination of paclitaxel and oral fluoropyrimidine is a candidate treatment for curatively resected gastric cancer at high risk of peritoneal recurrence (ie, serosa-positive tumours).14 However, no comparison has been done of concurrent and sequential regimens. Because of the poor nutrition of patients after gastrectomy20 and the interaction between paclitaxel and fluorouracil,21 we tested the effect of sequential paclitaxel followed by S-1 for locally advanced gastric cancer in the single group trial,22 with favourable results.
We did the Stomach cancer Adjuvant Multi-institutional group (SAMIT) trial for T4a or T4b23 gastric cancer to assess (1) the effect on survival of paclitaxel followed by oral fluoropyrimidine (sequential treatment) compared with fluoropyrimidine alone (monotherapy), and (2) the non-inferiority of UFT compared with S-1.24
Section snippets
Study design and participants
We did this phase 3, randomised controlled study at 230 hospitals in Japan. We used a two-by-two factorial design, with four treatment groups: UFT alone, S-1 alone, paclitaxel followed by UFT, and paclitaxel followed by S-1. This design enabled us to evaluate the superiority of sequential treatment compared with monotherapy as well as the non-inferiority of UFT compared with S-1. The design of the study has been described previously.24
Panel 1 shows the eligibility criteria. In the original
Results
Between Aug 3, 2004 and Sept 24, 2009, 1495 patients were randomly assigned to a treatment group (figure 1). 62 patients were excluded because of ineligibility (n=27), withdrawal of consent (n=25), or no data (n=10). 1368 (96%) patients were followed up. Baseline characteristics were well balanced between the four treatment groups (table 1). Full protocol treatment was completed by 215 (60%) of 359 patients in the UFT only group, 224 (62%) of 364 in the S-1 only group, 242 (68%) of 355 in the
Discussion
Sequential paclitaxel did not improve disease-free survival and UFT was not non-inferior to S-1; S-1 was superior to UFT as adjuvant treatment for T4a or T4b gastric cancer. These results suggest that S-1 monotherapy should remain the standard treatment for locally advanced gastric cancer in Japan.
To our knowledge, the SAMIT trial is the largest-ever adjuvant trial for gastric cancer. Few other large randomised adjuvant trials have been done for gastric cancer, especially after radical lymph
References (44)
- et al.
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Lancet
(2012) - et al.
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Lancet
(2009) - et al.
Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis
Cancer Treat Rev
(2010) - et al.
Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells
Biochem Pharmacol
(1999) - et al.
Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial
Lancet
(1999) - et al.
Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach
Crit Rev Oncol Hematol
(2005) - et al.
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Int J Cancer
(2010) - et al.
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
N Engl J Med
(2006) - et al.
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
N Engl J Med
(2007) - et al.
Efficacy of adjuvant chemotherapy using oral fluorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan
J Chemother
(2006)
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Nat Rev Clin Oncol
The role of taxanes in the management of gastroesphageal cancer
J Gastrointest Oncol
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
Lancet
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
J Clin Oncol
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
J Clin Oncol
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial
J Natl Cancer Inst
Paclitaxel chemotherapy for the treatment of gastric cancer
Gastric Cancer
Macroscopic serosal classification predicts peritoneal recurrence for patients with gastric cancer underwent potentially curative surgery
Ann Surg Oncol
Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients
World J Gastroenterol
JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer
Gastric Cancer
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial
J Clin Oncol
Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer
Br J Surg
Cited by (101)
Non-inferiority in cancer clinical trials was associated with more lenient margins and higher hypothesized outcome event rates
2021, Journal of Clinical EpidemiologyMultidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
2021, Surgical OncologyCitation Excerpt :In Asia, upfront surgery and postoperative chemotherapy is the standard treatment strategy for patients with LAGC [1]. The S-1 monotherapy regimen and the CapOx regimen are commonly used for patients with stage II disease based on the results of the ACTS-GC study [49], the CLASSIC study [50], and the other clinical trials [72–79]. For patients with stage III GC, the CapOx regimen and the S-1 plus docetaxel regimen are recommended [50,51], because the S-1 monotherapy regimen did not improve survival for this patient group [49].
Comment on: “Triceps skinfold-albumin index significantly predicts the prognosis of cancer cachexia: A multicentre cohort study” by Yin et al. - the authors reply
2023, Journal of Cachexia, Sarcopenia and MusclePostoperative Early Body Weight Loss Is a Risk Factor for Recurrence in Patients with pStage III Gastric Cancer
2023, Oncology (Switzerland)